

Return on Innovation



Global health R&D delivers for North Carolina



US government (USG) investment in global health R&D has delivered

\$410 million

to North Carolina research institutions*

5,900+ new jobs

for North Carolina†

North Carolina's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
Duke University	\$250.1 million
FHI 360	\$91.0 million
University of North Carolina	\$46.4 million
University of North Carolina Chapel Hill	\$13.4 million
RTI International	\$5.0 million
North Carolina State University Raleigh	\$2.9 million
Wake Forest University	\$553 thousand

Neglected diseases in North Carolina‡

HIV diagnoses	12,904
Tuberculosis cases	2,165
Malaria cases	272
Zika cases	102
Chikungunya cases	74

North Carolina industry in global health R&D


Bayer: Clayton, Morrisville, Research Triangle Park
BD: Research Triangle Park
GSK: Research Triangle Park, Zebulon
Merck & Co: Durham, Wilson
Novartis: Holly Springs, Wilson

Global health R&D at work in the Tar Heel State



RTI International, in partnership with TB Alliance, is supporting development of new drugs for tuberculosis. One new drug therapy, PaMZ, promises to dramatically shorten and simplify treatment for multidrug-resistant tuberculosis (MDR-TB). Today people with MDR-TB face up to two years of treatment with only a 50 percent success rate. This game-changing therapy now in late-stage development is expected to decrease treatment to 6 months and reduce costs by 90 percent.

North Carolina's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES*



89¢ of every dollar

the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, Malaria cases 2008-2014, Zika virus disease cases 2015-2017, Chikungunya virus disease cases 2014-2017.

§Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.